Crossmark

In vivo-measured Lewy body pathology is associated with neuropsychiatric symptoms across the Alzheimer’s disease continuum

Crossref DOI link: https://doi.org/10.1038/s41380-025-03400-7

Published Online: 2025-12-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Leffa, Douglas Teixeira https://orcid.org/0000-0002-4890-8451
Povala, Guilherme

Ferreira, Pamela C. L. https://orcid.org/0000-0003-2134-9829
Ferrari-Souza, João Pedro https://orcid.org/0000-0003-2183-1551
Bauer-Negrini, Guilherme

Rodrigues, Matheus Scarpatto

Amaral, Livia https://orcid.org/0009-0005-4488-763X
Lussier, Firoza Z.

Medeiros, Marina Scop https://orcid.org/0009-0009-4237-4565
Soares, Carolina https://orcid.org/0000-0002-2338-4495
Aguzzoli, Cristiano Schaffer https://orcid.org/0000-0002-7378-3830
Macedo, Arthur C.

Therriault, Joseph

Rosa-Neto, Pedro https://orcid.org/0000-0001-9116-1376
Tudorascu, Dana L.

Zimmer, Eduardo R. https://orcid.org/0000-0002-5349-0053
Bellaver, Bruna https://orcid.org/0000-0002-2212-3373
Pascoal, Tharick A.
Funding

Funding for this research was provided by:

Alzheimer's Association (24AARFD-1243899)

Alzheimer's Association (AARFD-22-923814)

Alzheimer's Association (AARFD-23-1150249)

Alzheimer's Association (AARFD-24-1313939)

Alzheimer's Association (24AACSF-1200375)

Alzheimer's Association (AARFD-22-974627)

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.951210/2024-00)

McGill University Faculty of Medicine student fellowship, and the Colin J Adair foundation fellowship

U.S. Department of Health & Human Services | NIH | National Institute on Aging (5R01AG073267)

U.S. Department of Health & Human Services | NIH | National Institute on Aging (5R01AG075336)
License Information

Text and Data Mining valid from 2025-12-14

Version of Record valid from 2025-12-14
More Information

Article History

Received: 20 March 2025

Revised: 10 November 2025

Accepted: 2 December 2025

First Online: 14 December 2025

Competing interests

: J.T. has served as a paid consultant for Neurotorium and Alzheon Inc, outside of the scope of the current work. E.R.Z. has served on the scientific advisory board or as a consultant for Nintx, Novo Nordisk, Magdalena Biosciences and Masima. He is also a co-founder and minority shareholder of Masima.

: Institutional Review Boards of all participating sites approved the ADNI study, and all research participants or their authorized representatives provided written informed consent. All methods were performed in accordance with the relevant guidelines and regulations.

Document is current

Any future updates will be listed below